GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzolytics Inc (OTCPK:ENZC) » Definitions » 9-Day RSI

Enzolytics (Enzolytics) 9-Day RSI

: 26.16 (As of Today)
View and export this data going back to 2008. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-18), Enzolytics's 9-Day RSI is 26.16.

The industry rank for Enzolytics's 9-Day RSI or its related term are showing as below:

ENZC's 9-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 38.435 vs ENZC: 26.16

Competitive Comparison

For the Biotechnology subindustry, Enzolytics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzolytics 9-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Enzolytics's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Enzolytics's 9-Day RSI falls into.



Enzolytics  (OTCPK:ENZC) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzolytics  (OTCPK:ENZC) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Enzolytics 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Enzolytics's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzolytics (Enzolytics) Business Description

Traded in Other Exchanges
N/A
Address
1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus.

Enzolytics (Enzolytics) Headlines

From GuruFocus

Enzolytics, Inc. Announces New Advisory Board Member

By ACCESSWIRE ACCESSWIRE 10-24-2022

Enzolytics to Develop Feline Monoclonal Antibodies

By ACCESSWIRE ACCESSWIRE 01-03-2023